% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wolf:131742,
author = {C. Wolf and A. Garding and K. Filarsky$^*$ and J. Bahlo and
S. Robrecht and N. Becker$^*$ and M. Zucknick and A. Rouhi
and A. Weigel and R. Claus and D. Weichenhan$^*$ and B.
Eichhorst and K. Fischer and M. Hallek and F. Kuchenbauer
and C. Plass$^*$ and H. Döhner and S. Stilgenbauer and P.
Lichter$^*$ and D. Mertens$^*$},
title = {{NFATC}1 activation by {DNA} hypomethylation in chronic
lymphocytic leukemia correlates with clinical staging and
can be inhibited by ibrutinib.},
journal = {International journal of cancer},
volume = {142},
number = {2},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2018-00048},
pages = {322 - 333},
year = {2018},
abstract = {B cell receptor (BCR) signaling is a key for survival of
chronic lymphocytic leukemia (CLL) cells, and BCR signaling
inhibitors are clinically active. However, relapse and
resistance to treatment require novel treatment options. To
detect novel candidate therapeutic targets, we performed a
genome-wide DNA methylation screen with custom arrays and
identified aberrant promoter DNA methylation in 2,192 genes.
The transcription factor NFATC1 that is a downstream
effector of BCR signaling was among the top hypomethylated
genes and was concomitantly transcriptionally upregulated in
CLL. Intriguingly, NFATC1 promoter DNA hypomethylation
levels were significantly variant in clinical trial cohorts
from different disease progression stages and furthermore
correlated with Binet disease staging and thymidine kinase
levels, strongly suggesting a central role of NFATC1 in CLL
development. Functionally, DNA hypomethylation at NFATC1
promoter inversely correlated with RNA levels of NFATC1 and
dysregulation correlated with expression of target genes
BCL-2, CCND1 and CCR7. The inhibition of the NFAT regulator
calcineurin with tacrolimus and cyclosporin A and the BCR
signaling inhibitor ibrutinib significantly reduced NFAT
activity in leukemic cell lines, and NFAT inhibition
resulted in increased apoptosis of primary CLL cells. In
summary, our results indicate that the aberrant activation
of NFATC1 by DNA hypomethylation and BCR signaling plays a
major role in the pathomechanism of CLL.},
keywords = {Biomarkers, Tumor (NLM Chemicals) / NFATC Transcription
Factors (NLM Chemicals) / PCI 32765 (NLM Chemicals) /
Protein Kinase Inhibitors (NLM Chemicals) / Pyrazoles (NLM
Chemicals) / Pyrimidines (NLM Chemicals)},
cin = {B061 / B060 / C060 / C010},
ddc = {610},
cid = {I:(DE-He78)B061-20160331 / I:(DE-He78)B060-20160331 /
I:(DE-He78)C060-20160331 / I:(DE-He78)C010-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28921505},
doi = {10.1002/ijc.31057},
url = {https://inrepo02.dkfz.de/record/131742},
}